Top Markets
#1 MowCat MowCat +365.77%
#2 Islamic Coin Islamic Coin +152.17%
#3 龙虾 (Lobster) 龙虾 (Lobster) +56.26%
#4 SODAX SODAX +54.53%
#5 Cortex Cortex +32.35%
#6 BNB Attestation Service BNB Attestation Service +25.37%
#7 DexNet DexNet +23.20%
#8 OpenEden OpenEden +19.04%
#9 Pons Pons +18.25%
#10 Akedo Akedo +17.84%
Coin of the day
MowCat MowCat
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Peringkat dalam Saham #7189
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Harga Saham
$38.45
Kapitalisasi Pasar
$1.68B
Perubahan (1 hari)
-1.24%
Perubahan (1 tahun)
50.36%
Negara
KR
Perdagangan D&D Pharmatech (347850)

Kategori

Healthcare
Pendapatan untuk D&D Pharmatech (347850)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari D&D Pharmatech, pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan D&D Pharmatech dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH